The objective of the present research protocol, a cross-over, subject-blinded, clinical
trial, is to correlate changes in brain activity with reduction in suicidal ideation in
response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a
rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal
properties that may be distinct from its effects on depression. This pilot study will be used
to determine (1) whether specific electroencephalogram (EEG) findings are correlated with
response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in
the treatment of acute SI.